AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23909911 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of retinopathy (3-step change in Early Treatment Diabetic Retinopathy Study score)
Number of subjects: 1365
Study 22011531 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection control strategies to reduce MRSA transmission
Number of subjects: 5512
Study 22011531 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-MRSA genotype (USA300, USA400, USA1000)
Number of subjects: 5512
Study 22011531 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular typing of MRSA isolates
Number of subjects: 5512
Study 19049340 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-011 (0.01 to 3.0 mg/kg intravenously or 0.03 to 0.1 mg/kg subcutaneously)
Number of subjects: 48
Study 19049340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 19049340 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-011
Number of subjects: 48
Study 17116057 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colposuspension (LC)
Number of subjects: 97
Study 17116057 — intervention group
Group type: COMPARATOR
Intervention: Vaginal suburethral slingplasty (SPARC)
Number of subjects: 97
Study 14993114 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/d)
Number of subjects: 121
Study 14993114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 121
Study 14993114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 14993114 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 121
Study 11732275 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (600 IU daily) and selegiline (10 mg daily)
Number of subjects: 67
Study 11732275 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment (Control)
Number of subjects: 67
Study 9164205 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin 50 mg/m2 for nine courses
Number of subjects: 607
Study 9164205 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2 plus cyclophosphamide 750 mg/m2 every 21 days for six courses
Number of subjects: 607
Study 8425936 — intervention group
Group type: EXPERIMENTAL
Intervention: SKT test battery
Number of subjects: 265
Study 8425936 — intervention group
Group type: EXPERIMENTAL
Intervention: SKT memory and attention factor scores
Number of subjects: 265
Study 2438553 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glucocorticosteroids
Number of subjects: 13
Study 2438553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 29316186 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 24
Study 29316186 — intervention group
Group type: COMPARATOR
Intervention: Renal denervation
Number of subjects: 24
Study 27062950 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention (10-week duration)
Number of subjects: 0
Study 27062950 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 23796239 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care (KMC)
Number of subjects: 50
Study 23796239 — intervention group
Group type: COMPARATOR
Intervention: Control group (without KMC)
Number of subjects: 50
Study 23525525 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 40
Study 23525525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20950457 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HBV/Hib2.5 [Kft]
Number of subjects: 299
Study 20950457 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HBV/Hib
Number of subjects: 299
Study 20950457 — intervention group
Group type: COMPARATOR
Intervention: DTPw-HBV/Hib2.5
Number of subjects: 299
Study 20950457 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HBV/Hib2.5 [Kft] and DTPw-HBV/Hib
Number of subjects: 299
Study 18259973 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (n = 78)
Number of subjects: 166
Study 18259973 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 82)
Number of subjects: 166
Study 20522483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathers
Number of subjects: 1303
Study 16293781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multitherapy
Number of subjects: 72
Study 16293781 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72
Study 12164596 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 per cent wt/vol. glucose
Number of subjects: 60
Study 12164596 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 per cent wt/vol. glucose
Number of subjects: 60
Study 12164596 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 60
Study 9725478 — intervention group
Group type: EXPERIMENTAL
Intervention: Megaloporous sustained-release tablets
Number of subjects: 24
Study 9725478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophil matrix tablets
Number of subjects: 24
Study 9725478 — intervention group
Group type: EXPERIMENTAL
Intervention: Floating slow-release tablets with food
Number of subjects: 24
Study 9725478 — intervention group
Group type: COMPARATOR
Intervention: Floating slow-release tablets without food
Number of subjects: 24
Study 9725478 — intervention group
Group type: COMPARATOR
Intervention: Rapid release oxprenolol tablets
Number of subjects: 24
Study 9725478 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting tablets (sustained-release)
Number of subjects: 24
Study 7913498 — intervention group
Group type: EXPERIMENTAL
Intervention: E2078 (5.0 to 10.0 mg, i.m.)
Number of subjects: 21
Study 7913498 — intervention group
Group type: EXPERIMENTAL
Intervention: E2078 (single dose)
Number of subjects: 21
Study 7913498 — intervention group
Group type: EXPERIMENTAL
Intervention: E2078 (repeated dose, 5.0 mg t.i.d. for 4 and 1/3 days)
Number of subjects: 21
Study 7913498 — intervention group
Group type: EXPERIMENTAL
Intervention: E2078 (repeated doses)
Number of subjects: 21
Study 7913498 — intervention group
Group type: EXPERIMENTAL
Intervention: E2078 (single administration)
Number of subjects: 21
Study 3189201 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 1938
Study 3189201 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 1938
Study 3189201 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1938
Study 11891095 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (15 mg/kg per day)
Number of subjects: 24
Study 11891095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (20-25 mg/kg per day)
Number of subjects: 24
Study 30101910 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted R-CHOP doses according to a unified dose-attenuation system (UNI group)
Number of subjects: 115
Study 30101910 — intervention group
Group type: COMPARATOR
Intervention: Adjusted R-CHOP doses according to physicians' decisions (PHY group)
Number of subjects: 115
Study 30101910 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged >70 years in the UNI group
Number of subjects: 115
Study 30101910 — intervention group
Group type: COMPARATOR
Intervention: Patients aged >70 years in the PHY group
Number of subjects: 115
Study 27020664 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent thrombosis (ST) in patients with AMI after PCI
Number of subjects: 136
Study 27020664 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ST
Number of subjects: 136
Study 27020664 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of ST
Number of subjects: 136
Study 24842494 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone graft sealing
Number of subjects: 201
Study 24842494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement sealing
Number of subjects: 201
Study 24842494 — intervention group
Group type: COMPARATOR
Intervention: Unsealed canal
Number of subjects: 201
Study 22366446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) - 12 twice-weekly 60 min sessions
Number of subjects: 59
Study 22366446 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 59
Study 22366446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 59
Study 20177349 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (180 microg menakinon‐7)
Number of subjects: 94
Study 20177349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 18691211 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedics with extended skills (PPs) treating patients in the community.
Number of subjects: 2025
Study 18691211 — intervention group
Group type: COMPARATOR
Intervention: Standard practice of EMS transfer and ED treatment (Control).
Number of subjects: 2025
Study 15764767 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 250 microg ex-valve (220 microg ex-actuator) four puffs twice daily
Number of subjects: 14
Study 15764767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (CIC), 200 microg ex-valve (160 microg ex-actuator) four puffs twice daily
Number of subjects: 14
Study 15764767 — intervention group
Group type: COMPARATOR
Intervention: Ciclesonide (CIC)
Number of subjects: 14
Study 15764767 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 14
Study 12463328 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line microaerosol filter
Number of subjects: 26
Study 12463328 — intervention group
Group type: COMPARATOR
Intervention: Without in-line microaerosol filter
Number of subjects: 26
Study 10603631 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAp levels in pleural fluid > or = 40 IU and ADA1/ADAp ratio < or = 0.42
Number of subjects: 103
Study 10603631 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAp levels in TB group
Number of subjects: 103
Study 10603631 — intervention group
Group type: COMPARATOR
Intervention: ADAp levels in non-TB group
Number of subjects: 103
Study 10603631 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA1/ADAp ratio in TB group
Number of subjects: 103
Study 10603631 — intervention group
Group type: COMPARATOR
Intervention: ADA1/ADAp ratio in non-TB group
Number of subjects: 103
Study 10603631 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ADAp levels with monocyte macrophages
Number of subjects: 103
Study 10603631 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ADAp levels with lymphocytes
Number of subjects: 103
Study 7731621 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (received information about their diagnostic procedure)
Number of subjects: 803
Study 7731621 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (did not receive information, control group)
Number of subjects: 803
Study 2119847 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual regarding of feeds over 48 h (regimen 1)
Number of subjects: 74
Study 2119847 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid regarding of feeds over 16 h (regimen 2)
Number of subjects: 74
Study 2119847 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial starvation followed by full normal feeds at 24 h (regimen 3)
Number of subjects: 74
Study 533454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 20
Study 533454 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin
Number of subjects: 20
Study 30897241 — intervention group
Group type: EXPERIMENTAL
Intervention: Late evening food consumption (TLEE after 21:00)
Number of subjects: 2642
Study 30897241 — intervention group
Group type: EXPERIMENTAL
Intervention: Late evening food consumption (TLEE)
Number of subjects: 2642
Study 29057609 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made knee-high cast (BTCC)
Number of subjects: 60
Study 29057609 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made ankle-high cast shoe
Number of subjects: 60
Study 29057609 — intervention group
Group type: COMPARATOR
Intervention: Prefabricated ankle-high forefoot-offloading shoe (FOS)
Number of subjects: 60
Study 29057609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean peak pressure at ulcer site for BTCC
Number of subjects: 60
Study 29057609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean peak pressure at ulcer site for cast shoe
Number of subjects: 60
Study 29057609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean peak pressure at ulcer site for FOS
Number of subjects: 60
Study 29057609 — intervention group
Group type: EXPERIMENTAL
Intervention: Stride count for BTCC
Number of subjects: 60
Study 29057609 — intervention group
Group type: EXPERIMENTAL
Intervention: Stride count for cast shoe
Number of subjects: 60
Study 29057609 — intervention group
Group type: EXPERIMENTAL
Intervention: Stride count for FOS
Number of subjects: 60
Study 29057609 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of 2-week intervals with device worn <50% for BTCC
Number of subjects: 60
Study 29057609 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of 2-week intervals with device worn <50% for cast shoe
Number of subjects: 60
Study 29057609 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of 2-week intervals with device worn <50% for FOS
Number of subjects: 60
Study 26795874 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (12 mg per day after uptitration from 3 mg per day over 12 weeks)
Number of subjects: 130
Study 26795874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 26795874 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 130
Study 24652865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for community-dwelling older adults
Number of subjects: 241
Study 22192672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril, Telmisartan, or both (exact dosages not specified)
Number of subjects: 9603
Study 20943882 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose PCV
Number of subjects: 100
Study 20943882 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose PCV
Number of subjects: 100
Study 20943882 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated group
Number of subjects: 100
Study 20943882 — intervention group
Group type: EXPERIMENTAL
Intervention: 23vPPS booster
Number of subjects: 100
Study 20943882 — intervention group
Group type: COMPARATOR
Intervention: 0-dose PCV
Number of subjects: 100
Study 17033616 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 29
Study 17033616 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 29
Study 17033616 — intervention group
Group type: EXPERIMENTAL
Intervention: Water and Saline (paired data)
Number of subjects: 29
Study 16351367 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-manipulated success (Studies 1 and 2)
Number of subjects: 0
Study 16351367 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined highly positive events in the future (Study 3)
Number of subjects: 0
Study 11991475 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) - 3 sessions of 3000 shockwaves/session at 0.2 mJ/mm2, weekly intervals for Group 1 (25 heels)
Number of subjects: 47
Study 11991475 — intervention group
Group type: COMPARATOR
Intervention: Conventional conservative treatment (nonsteroidal anti‐inflammatory drugs, heel cup, orthoses and/or shoe modifications, local steroid injections, electrotherapy) for Group 2 (24 heels)
Number of subjects: 47
Study 11254464 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich beverage (12.5%) (n = 8)
Number of subjects: 15
Study 11254464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 15
Study 9730795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary hypertension group (n = 17)
Number of subjects: 26
Study 9730795 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pulmonary hypertension group (n = 9)
Number of subjects: 26
Study 9730795 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 26
Study 9730795 — intervention group
Group type: EXPERIMENTAL
Intervention: PH group (n = 17)
Number of subjects: 26
Study 9730795 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-PH group (n = 9)
Number of subjects: 26
Study 7800166 — intervention group
Group type: EXPERIMENTAL
Intervention: SER282 (20 mg/ml)
Number of subjects: 36
Study 7800166 — intervention group
Group type: COMPARATOR
Intervention: Amitryptiline (AMI, 50 mg)
Number of subjects: 36
Study 7800166 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 36
Study 3154631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil 240 mg
Number of subjects: 13
Study 3154631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 168650 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol
Number of subjects: 57
Study 168650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 168650 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 57
Study 168650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 57
Study 168650 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Clofibate or Colestipol, or Clofibrate and Cholestyramine)
Number of subjects: 57
Study 30316810 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking (consumption of five or more doses of alcohol on a single occasion)
Number of subjects: 6285
Study 30316810 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent/heavy drinking (alcohol consumption on six or more days)
Number of subjects: 6285
Study 30316810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 6285
Study 30316810 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of marijuana
Number of subjects: 6285
Study 30316810 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of inhalant drugs
Number of subjects: 6285
Study 30316810 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a drunk relative
Number of subjects: 6285
Study 30316810 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice of bullying
Number of subjects: 6285
Study 30316810 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal aggression
Number of subjects: 6285
Study 30316810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate/low school grades
Number of subjects: 6285
Study 30316810 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical aggression
Number of subjects: 6285
Study 31456106 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic total/subtotal colectomy
Number of subjects: 82
Study 31456106 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic total/subtotal colectomy
Number of subjects: 82
Study 25736589 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training (3 times weekly for 16 weeks)
Number of subjects: 21
Study 25736589 — intervention group
Group type: COMPARATOR
Intervention: Control period (16 weeks before training)
Number of subjects: 21
Study 22575238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical valrubicin (800 mg) instillations, 6 weekly doses
Number of subjects: 80
Study 22575238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical valrubicin (800 mg) instillations, 9 weekly doses
Number of subjects: 80
Study 22575238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical valrubicin (800 mg) instillations, 6 weekly doses (pivotal trial)
Number of subjects: 80
Study 22575238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical valrubicin (800 mg) instillations
Number of subjects: 80
Study 21715575 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg MF59 adjuvanted vaccine
Number of subjects: 2
Study 21715575 — intervention group
Group type: COMPARATOR
Intervention: 3.75 μg MF59 adjuvanted vaccine
Number of subjects: 2
Study 21715575 — intervention group
Group type: COMPARATOR
Intervention: 15 μg nonadjuvanted vaccine
Number of subjects: 2
Study 21715575 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59 adjuvanted vaccines
Number of subjects: 2
Study 20033527 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic chest radiography using a dynamic flat-panel detector (FPD) system
Number of subjects: 20
Study 16957425 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 520
Study 16957425 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 520
Study 16957425 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 520
Study 16957425 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 520
Study 15103753 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐catheter ablation
Number of subjects: 239
Study 15103753 — intervention group
Group type: COMPARATOR
Intervention: 5‐catheter ablation (control)
Number of subjects: 239
Study 11691700 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced consent procedure (computerized presentation with sequential bullet points and summaries)
Number of subjects: 69
Study 11691700 — intervention group
Group type: COMPARATOR
Intervention: Routine consent procedure
Number of subjects: 69
Study 9103794 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable prophylaxis angle
Number of subjects: 30
Study 9103794 — intervention group
Group type: COMPARATOR
Intervention: Autoclavable prophylaxis angle
Number of subjects: 30
Study 8104596 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission induction with vincristine (VCR), prednisolone (PRED), and L-asparaginase (L-Asp)
Number of subjects: 212
Study 8104596 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation course with cyclophosphamide (CP) and cytarabine (AraC) for SR and IR groups; two courses for HR group
Number of subjects: 212
Study 8104596 — intervention group
Group type: EXPERIMENTAL
Intervention: Central nervous system prophylaxis randomized using either cranial irradiation 18 Gy + 5 intrathecal methotrexate (IT MTX) or triple IT with maintenance
Number of subjects: 212
Study 8104596 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement cycles during maintenance therapy (6-mercaptopurine+MTX)
Number of subjects: 212
Study 3097178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (0.22 mg X kg‐1, range 0.15‐0.38)
Number of subjects: 0